|Registry of biomedical companies:
[(]  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 476 active entries
Salzdahlumer Str. 196
Phone: 0049 531 260 12 66
Fax: 0049 531 260 11 59
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
All products of LIONEX are developed and manufactured entirely in Braunschweig, Germany
Lionex is a growing biotech company dedicated to modern biomedicine for human health. Lionex is developing protein-focused technologies to enable the accelerated identification, development and production of new and improved products (diagnostics, drugs and vaccines) for combating major diseases, e.g. tuberculosis/HIV, heart diseases and cancer. Products: -Development of specific and rapid Tuberculosis diagnostic kits.
-Several serological kits (IgG,-A and -M) for Tuberculosis diagnosis have been developed showing high sensitivities and specifcities for pulmonary and extra-pulmonary TB.
LIONEX has introduced a new TB IGRA test called LIOFERON for the diagnosis of infection with Mycobacterium tuberculosis (www.lionex.de).
LIONEX TB-ST+2, a second generation TB rapid tests for use with serum and blood has been launched. It provids results in 15 minutes and shows high specificity and high sensitivity, specially in smear negative active TB (an independent evaluation has confirmed these results in IGRA positive TB patients (manuscript in press).
-LIONEX continues to increase its panel of high quality mycobacterial antigens. The recombinant antigens are being used to develop test for sero-diagnosis of TB. Special attention is being given to cost-effective and rapid tests.
-In addition, based on proprietary methods rapid molecular tests have been developed for differentiating tuberculous bacteria from the nontuberculous ones.
LIONEX has also on the market rapid tests such as CRP, D-Dimer, Troponin I. Many more are in development.
-A rapid 3 hour test for differentiating M. tuberculosis from M. bovis has been developed.
Contract manufacturing: Large quantities of recombinant antigens, DNA, LAM. Also, OEM of rapid tests is regularly done.
Last update of this entry: September 29, 2021